Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.79 USD | +0.34% | -1.88% | +19.72% |
May. 29 | Catalent Shareholders Approve Deal With Novo Holdings | MT |
May. 29 | Catalent stockholders approve deal with Novo Holdings | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.72% | 9.73B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs